臺灣博碩士論文加值系統

人類大腸直腸癌之病發率高居台灣十大癌症死因第一名，且病例有逐年上升趨勢。目前醫療上對於大腸直腸癌缺乏有效的早期檢測方法，使之大腸直腸癌病人無法被早期診治。目前研究指出，一些腫瘤相關抗原會對不同癌症病人自身自體免疫抗體產生反應。故本研究目的希望偵測大腸直腸癌病人血清中自體抗體與組織之抗原表現，以進一步評估其靈敏度、專一性與表現率並用於癌症診斷上。本研究初期挑選出11個大腸直腸癌之候選相關抗原用來偵測病人血清中的抗體反應，並依據初步偵測結果將研究主軸集中於Annexins此抗原。初步推測大量表現Annexins可能會誘發自體抗體反應，而尚未有研究證實可從癌症病人血清中測得抗體反應。研究中以Annexins重組蛋白作為抗原並利用酵素連結免疫試驗(ELISA)與西方墨點法(Western blotting)分別偵測220個不同Dukes’期數之大腸直腸癌病人及216個健康捐贈者血清中對於Annexins的自體抗體反應，同時依據ELISA結果訂定出適合之cut-off值。研究結果顯示，大腸直腸癌病人與健檢者血清中具顯著差異性的自體抗體反應，其靈敏度與專一性分別為68 % 與 74 %。其靈敏度更可藉由結合臨床CEA數值(CEA > 5 ng/ml) 達到83 %，其中抗體反應比率為Dukes’後期高於Dukes’前期。另外利用Annexin單株抗體以螢光免疫染色法(IHC)與西方墨點法(Western blotting)方法偵測60對大腸直腸癌病人組織中Annexin表現情形。結果顯示有45 % 病人組織中其抗原上升表現率高於兩倍，同時癌組織亦較正常組織具有高度表現性(P < 0.001)。故藉由研究偵測Annexin自體抗體反應與表現情形，可作為大腸直腸癌在臨床診斷與癒後評估上的另一個參考指標。

Human colorectal cancer (CRC) has been listed as one of the most present cancer in Taiwan. According to recent studies, some cancer patients possessed autologous antibody could recognize different tumor-associated antigens (TAAs). Therefore, the aim of this study was to detect auto-antibody and antigen in the CRC patient’s serum and tissue, then measure their sensitivity, specificity and prevalence for cancer diagnosis. In the initial investigation, we seleted eleven TAAs to detect their corresponding antibodies in patient’s serum and finally we focus on Annexins. Here, we are the first to demonstrate that over-expression of Annexins presumably induces auto-antibody response. We have examined 220 sera samples from CRC patients and 216 healthy volunteers’ samples to observe and correlate the autoantibodies response to Annexins in different Dukes’ stages of CRC. By using Western blot and ELISA analysis with recombinant Annexins as antigen and an appropriate cut-off point, we demonstrated that a high level of Annexins autoantibodies was more significantly presented in CRC patients than healthy controls with a 68 % and 74 % of sensitivity and specificity, respectively. In addition, the diagnostic sensitivity could be reached to 83 % determined by either positive antibody response or level of CEA (CEA＞5 ng/ml). We also found Annexins autoantibody response occurred more frequently in Dukes’ advanced stage than early stages of CRC. Alternatively, we also detected the expression of Annexin in 60 tissue pairs of CRC patients by IHC and Western blotting. Our finding revealed that the Annexin protein level was relatively up-regulated (expression ratio > 2) in 45 % CRC patients. Such result demonstrated significantly higher level of Annexin protein expression in tumor tissues than in normal tissues (P < 0.001). In conclusion, the measurement of anti-Annexin autoantibodies response and Annexin expression could be an alternative approach and useful diagnostic and prognostic method for CRC patients.

指導教授推薦書
口試委員會審定書
長庚大學碩士論文著作授權書…………………………………..………............iii
誌謝…………………………………………………………………......................iv
中文摘要…………………………………………………………….......................v
英文摘要……………………………………………………………......................vi
縮寫表…………………………………………………………………………….vii
目錄………………………………………………………………………………..ix
附圖目錄………………………………………………………………………….xii
附表目錄…………………………………………………………………………xiv
第一章 研究動機與背景介紹 ……………………………………………….......1
1.1 研究動機……………………………………………………………..1
1.2 人類大腸直腸癌(Human Colorectal Cancer)……………..………...3
1.2.1 大腸直腸癌的盛行狀況……………………………………….3
1.2.2 大腸直腸癌病因……………………………………………….3
1.2.3 大腸直腸癌的病狀…………………………………………….5
1.2.4 大腸直腸癌的診斷…………………………………………….6
1.2.5 大腸直腸癌的分期…………………………………………….8
1.2.6 大腸直腸癌的治療…………………………………………...12

1.3 大腸直腸癌之癒後(Prognosis)…………………………..................15
1.4大腸直腸癌之腫瘤抗原(Tumor-associated antigens-TAAs) ……....17
1.5大腸直腸癌對抑癌藥物之低治療率……....……………..................19
第二章 材料與方法……………………………………………………………...21
2.1 實驗材料………………………………………................................21
2.2 實驗方法………………………………………................................23
2.2.1 大腸直腸癌抗原基因之選殖………………………………...23
2.2.2 重組蛋白(recombinant protein) 之表現與純化……………..31
2.2.3 酵素連結免疫試驗(ELISA)………………………………….34
第三章 實驗結果………………………………………………………………...36
3.1 Proteomics方法尋找大腸直腸癌之腫瘤相關抗原………………...36
3.1.1 Proteomics方法找尋大腸直腸癌組織up-regulated protein…36
3.1.2 腫瘤相關抗原之基因轉殖…………………………………...37
3.2 表現選殖基因之重組蛋白與純化……………................................39
3.2.1 基因選殖重組蛋白之表現…………………………………...39
3.2.2 純化基因選殖之重組蛋白…………………………………...40
3.3 篩檢大腸直腸癌病人及健檢者血清之抗原抗體反應……………42
3.3.1 建立血清抗原抗體反應之Western blot format……………..42



3.3.2 大量以Western blot方法偵測大腸直腸癌病人與健康者 血清對Annexins之自體抗體反應……………………………...43
3.3.3 建立偵測血清抗體反應之ELISA format同時大量篩檢大腸直腸癌與健康者血清對Annexins之抗體反應…………....45
3.4 評估其他癌症病人血清對Annexins之抗體反應……………........47
3.5 偵測大腸直腸癌病人組織中Annexin之表現情形……………….48
3.6 偵測大腸直腸癌病人血清中Annexin之表現…………………….50
第四章 研究討論………………………………………………………………...51
第五章 結論….…………...…………………………….………………………..53
參考文獻…………..……………………………………………………………...55
附錄……………………………………………………………………………….72
附圖…………………………………………………………………………….72
附表…………………………………………………………………………….91
Supplementary data……..……………………………………………………….104

行政院衛生署 - http://www.doh.gov.tw/statistic 。
鄭智勇, 林繼昌 編著。1991年。《大腸直腸癌之病理分類、分期與預後》。國防醫學 第十二卷第三期；217-221。
李祥, 賴世偉, 黃金財 編著。2001年。《大腸直腸癌》。基層醫學 第十六卷第八期：192-198。
馬克 . 波恰品醫師 (Mark Bennett Pochapin. M. D.) 著《What your doctor may not tell you about colorectal cancer》， 鄭清榮譯 《大腸癌診療室》。 台北，原水文化，2005年。
Astler, V. B., and Coller, F. A. (1954). The prognosis significant of direct extension of carcinoma of the colon and rectum. Ann. Surg. 139:846-851.
Angelopoulou, K., Stratis, M., and Diamandis, E. P. (1997). Humoral immune response against p53 protein in patients with colorectal carcinoma. Int. J. Cancer. 70:46-51.
Abeloff. (2000). Churchill livingstone. Clin. Oncol. 2nd ed. New York. 1611-1617.
Anwar, S., Frayling, I. M., and Scott, N. A. (2004). Systematic review of genetic influences on the prognosis of colorectal cancer. Br. J. Surg. 91:1275-1291.
Agudo, R., Arias, A., Pariente, N., Perales, C., Escarmis, C., Jorge, A., Marina, A., and Domingo, E. (2008). Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J. Mol. Biol. 382:652-666.
Bast RC, Jr., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H. Jr., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., Somerfield, M. R., and American Society of Clinical Oncology Tumor Markers Expert Panel. (2001). 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19:1865-1878.
Brichory, F. M., Misek, D. E., Yim, A. M., Krause, M. C., Giordano, T. J., Beer, D. G., and Hanash, S. M. (2001). An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 98:9824-9829.
Broll, R., Duchrow, M., Oevermann, E., Wellm, C., Schwandner, O., Schimmelpenning, H., Roblick, U. J., Bruch, H. P., and Windhovel, U. (2001). p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int. J. Colorectal Dis. 16:22-27.
Bergmann, U., and Beger, H. G. (2003). Endoscopic mucosal resection for advanced non-polypoid colorectal adenoma and early stage carcinoma. Surg. Endosc. 17:475-479.
Bai, X. F., Ni, X. G., Zhao, P., Liu, S.M., Wang, H.X., Guo, B., Zhou, L. P., Liu, F., Zhang, J.S., Wang, K., Xie, Y. Q., Shao, Y. F., and Zhao, X. H. (2004). Overexpression of annexin I in pancreatic cancer and its clinical significance. World J. Gastroenterol. 10:1466-1470.
Bijnsdorp, I. V., Comijn, E. M., Padron, J. M., Gmeiner, W. H., and Peters, G. J. (2007). Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition. Oncol. Rep. 18:287-291.
Brody, J. D., Goldstein, M. J., Czerwinski, D. K., and Levy, R. (2009). Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood. 113:85-94.
Chen, T. H., Yen, M. F., Lai, M. S., and Koong, S. L. (1999). Evaluation of a selective screening for colorectal carcinoma: The Taiwan Multicenter Cancer Screening (TAMCAS) project. Cancer. 86:1116-1128.
Choi, S., Kobayashi, M., Wang, J., Habelhah, H., Okada, F., Hamada, J., Moriuchi, T., Totsuka, Y., and Hosokawa, M. (2000). Activated leukocyte cell adhesion molecule (ALCAM) and annexin II are involved in the metastatic progression of tumor cells after chemotherapy with Adriamycin. Clin. Exp. Metastasis. 18:45-50.
Chen, L. T., and Whang-Peng, J. (2004). Current status of clinical studies for colorectal cancer in Taiwan. Clin. Colorectal Cancer. 4:196-203.
Duffy, M. J., Van-Dalen, A., Haglund, C., Hansson, L., Holinski-Feder, E., Klapdor, R., Lamerz, R., Peltomaki, P., Sturgeon, C., and Topolcan, O. (2007). Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer. 43:1348-1360.
Duncan, R., Carpenter, B., Main, L. C., Telfer, C., and Murray, G. I. (2008). Characterisation and protein expression profiling of annexins in colorectal cancer. Br. J. Cancer. 98:426-433.
Fan, C. W., Fan, H. A., Hsu, S. H., Chan, C. C., Chen, S. Y., Hsu, Y. H., and Chan, E. C. (2004). An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer. Cancer Lett. 214:181-188.
Fischer, J. A., Muller-Weeks, S., and Caradonna, S. J. (2008). Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase. Cancer Res. 66:8829-8837.
Gorlick, R., and Bertino, J. R. (1999). Drug resistance in colon cancer. Semin. Oncol. 26:606-611.
Grothey, A., and Schmoll, H. J. (2001). New chemotherapy approaches in colorectal cancer. Curr. Opin. Oncol. 13:275-286.
Gerke, V., and Moss, S. E. (2003). Annexins: from structure to function. Physiol. Rev. 82:331-371.
Gerke, V., Creutz, C. E., and Moss, S. E. (2005). Annexins: linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. 6:449-461.
Gmeiner, W. H. (2005). Novel chemical strategies for thymidylate synthase inhibition. Curr. Med. Chem. 12:191-202.
Grem, J. L. (2005). Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer. Semin. Oncol. 32:120-127.
Galmarini, C. M., Warren, G., Kohli, E., Zeman, A., Mitin, A., and Vinogradov, S. V. (2008). Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol. Cancer Ther. 7:3373-3380.
Han, E. K., Tahir, S. K., Cherian, S. P., Collins, N., and Ng, S. C. (2000). Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br. J. Cancer. 83:83-88.
Hayes, M. J., and Moss, S. E. (2004). Annexins and disease. Biochem. Biophys. Res. Commun. 322:1166-170.
Hartmann, T. B., Bazhin, A. V., Schadendorf, D., and Eichmuller, S. B. (2005). SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int. J. Cancer. 114:88-93.
Haller, D. G., Rothenberg, M. L., Wong, A. O., Koralewski, P. M., Miller, W. H. Jr., Bodoky, G., Habboubi, N., Garay, C., and Olivatto, L. O. (2008). Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J. Clin. Oncol. 26:4544-4550.
Hamilton, S. R. (2008). Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod. Pathol. 21:S23-S30.
Hind, D., Tappenden, P., Tumur, I., Eggington, S., Sutcliffe, P., and Ryan, A. (2008). The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol. Assess. 12:iii-ix, xi-162.
Kourie, J. I., and Wood, H. B. (2000). Biophysical and molecular properties of annexin-formed channels. Prog. Biophys. Mol. Biol. 73:91-134.
Kunth, A., Jager, D., and Jager, E. (2000). Cancer immunotherapy in clinical oncology. Cancer Chemother. Pharmacol. 46:S46-S51.
Koziol, J. A., Zhang, J. Y., Casiano, C. A., Peng, X. X., Shi, F. D., Feng, A. C., Chan, E. K., and Tan, E. M. (2003). Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. 9:5120-5126.
Kocer, B., McKolanis, J., and Soran, A. (2006). Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC. Gastroenterol. 6:4.
Kuespert, K., Pils, S., and Hauck, C. R. (2006). CEACAMs: their role in physiology and pathophysiology. Curr. Opin. Cell Biol. 18:565-571.
Kim, S. Y., Hong, Y. S., Kim, B. C., Park, J. W., Chio, H. S., Jeong, S. Y., Kim, D. Y., Hong, C. W., Sohn, D. K., and Jung K. H. (2008). A phase II sdudy of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. Invest. New Drugs. DOI 10.1007/s10637-008-9177-5.
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr., and ASCO. (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24:5313-5327.
Lim, L. H., and Pervaiz, S. (2007). Annexin 1: the new face of an old molecule. FASEB. J. 21:968-975.
Ladd, J., Lu, H., Taylor, A. D., Goodell, V., Disis, M. L., and Jiang, S. (2008). Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf. B. Biointerfaces. COLSUB-3467, No. of pages 6.
Moertel, C. G., O’Fallon, J. R., Go, V. L., O’Connell, M. J., and Thynne, G. S. (1986). The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer. 58:603-610.
Marrelli, D., Roviello, F., De, S. A., and Farnetani, M. (1999). Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology. 57:55-62.
Munro, A. J., Lain, S., and Lane, D. P. (2005). P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br. J. Cancer. 92:434-444.
Montemurro, M., Achtari, L., Roth, A., Halkic, N., Luthi, F., Ozsahim, M., Denys, A., Bauer, J., Demartines, N., and Leyvraz, S. (2008). Systemic treatment of metastatic colorectal cancer. Rev. Med. Suisse. 21:1254-1257.
Nazli, O., Bozdag, A. D., Tansug, T., and Kir, R. (2000). The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology. 47:1750-1752.
Popat, S., Hubner, R., and Houlston, R. S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23:609-618.
Popat, S., Wort, R., and Houlston, R. S. (2006). Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC. Cancer. 6:150.
Pasetto, L. M., Falci, C., Rizzo, E., De Salvo, G. L., Gasparini, G., D’ Andrea, M., Bajetta, E., Platania, M., Alabiso, O., Miraqlia, S., Oniqa, F., Biason, R., Chetri, M. C., Fedele, P., Massara, G., Romaniello, I., Giordano, M., Luchena, G., Buzzi, F., Ricotta, R., Siena, S., and Monfardini, S. (2008). Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. Anticancer Res. 28:1813-1820.
Rand, J. H. (2000). The annexinopathies: a new category of diseases. Biochim. Biophys. Acta. 1498:169-173.
Renner, C., Trumper, L., and Pfreundschuh, M. (2000). Tumour vaccines: a new immunotherapeutic approach in oncology. Ann. Hematol. 79:651-659.
Rescher, U., and Gerke, V. (2004). Annexins-unique membrane binding proteins with diverse functions. J. Cell Sci. 117:2631-2639.
Rubin, P., and Hansen, J. T., ”TNM staging atlas” , Lippincott Williams & Wilkins, 2008.
Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., and Pfreundschuh, M. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA. 92:11810-11813.
Sahin, U., Tureci, O., and Pfreundschuh, M. (1997). Serological identification of human tumor antigens. Curr. Opin. Immunol. 9:709-716.
Schmoll, H. J., Buchele, T., Grothey, A., and Dempke, W. (1999). Where do we stand with 5-fluorouracil ? Semin. Oncol. 26:589-605.
Smith, T. J., Davidson, N. E., Schapira, D. V., and Grunfeld, E. (1999). American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J. Clin. Oncol. 17:1080-1082.
Scholzel, S., Zimmermann, W., Schwarzkopf, G., and Grunert, F. (2000). Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am. J. Pathol. 156:595-605.
Soussi, T. (2000). p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60:1777-1788.
Shawler, D. L., Bartholomew, R. M., Garrett, M. A., Trauger, R. J., Dorigo, O., Van Beveren, C., Marchese, A., Ferre, F., Duffy, C., Carlo, D. J., Sherman, L. A., Gold, D. P., and Sobol, R. E. (2002). Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin. Exp. Immunol. 129:99-106.
Storojeva, I., Boulay, J. L., and Heinimann, K. (2005). Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol. Rep. 14:241-249.
Suh, K. W., Kim, J. H., and Kim, Y. B. (2005). Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J. Gastrointest Surg. 9:336-342.
Sharma, M. R., Koltowski, L., Ownbey, R. T., Tuszynski, G. P., and Sharma, M. C. (2006). Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp. Mol. Pathol. 81:146-156.
Shimada, H., Kuboshima, M., Shiratori, T., Nabeya, Y., Takeuchi, A., Takagi, H., Nomura, F., Takiguchi, M., Ochiai, T., and Hiwasa, T. (2007). Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int. J. Oncol. 30:97-103.
Syed, S. P., Martin, A. M., Haupt, H. M., Arenas-Elliot, C. P., and Brooks, J. J. (2007). Angiostatin receptor annexin II in vascular tumors including angio-sarcoma. Hum. Pathol. 38:508-513.
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A. Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., Lenz, H. J., Borg, C., Middleton, G., Kroning, H., Luppi, G., Kisker, O., Zubel, A., Langer, C., Kopit, J., and Burris H. A. 3rd. (2008). EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:2311-2319.
Tung, J. Y., Chen, G. H., and Yeh, C. L. (1986). Colorectal cancer. J. Chin. Oncol. Soc. 2:11-16.
Thompson, J. A., Grunert, F., and Zimmermann, W. (1991). Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J. Clin. Lab. Anal. 5:344-366.
Tas, F., Aydiner, A., Topuz, E., and Yasasever, V. (2000). Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. J. Exp. Clin. Cancer Res. 19:477-481.
Tang, R., Ko, M. C., Wang, J. Y., Changchien, C. R., Chen, H. H., Chen, J. S., Hsu, K. C., Chiang, J. M., and Hsieh, L. L. (2001). Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer. 94:859-863.
Takahashi, Y., Takeuchi, T., Sakamoto, J., and Touge, T. (2003). The usefulness of CEA and/or CA 19-9 in monitoring for recurrence in gastric cancer patients: A prospective clinical study. Gastric Cancer. 6:142-145.
Toubi, E., and Shoenfeld, Y. (2007). Protective autoimmunity in cancer (review). Oncol. Rep. 17:245-251.
Tsujimoto, S., Fujimoto, K., Okajima, E., Ozono, S., Okajima, E., and Hirao, Y. (2008). 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil. Int. J. Clin. Oncol. 13:138-143.
Umar, A., Boland, C. R., and Terdiman, J. P. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl. Cancer Inst. 96:261-268.
Van Kuilenburg, A. B. (2004). Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer. 40:939-950.
Vishwanatha, J. K., Salazar, E., and Gopalakrishnan, V. K. (2004). Absence of annexin I expression in B-cell non-Hodgkin’s lymphomas and cell lines. BMC. Cancer. 4:8.
Van, C. E., and Geboes, K. (2007). The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 21:1089-1108.
Vakhabova, J. V., Semenov, N. N., Dobrova, N. V., and Lichinitser, M. R. (2008). Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer. Bull. Exp. Biol. Med. 145:249-251.
Wu, K. L., and Cheng, T. C. (1983). Carcinoma of colon. Chin. Med. J. 32:378-381.


Wang, W. S., Lin, J. K., Chiou, T. J., Liu, J. H., Fan, F. S., Yen, C. C., Lin, T. C., Jiang, J. K., Yang, S. H., Wang, H. S., and Chen, P. M. (2000). Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn. J. Clin. Oncol. 30:12-16.
Wang, W. S., Lin, J. K., Chiou, T. J., Liu, J. H., Fan, F. S., Yen, C. C., Lin, T. C., Jiang, J. K., Yang, S. H., Wang, H. S., and Chen, P. M. (2002). CA 19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 49:160-164.
Westra, J. L., Plukker, J. T., and Buys, C. H. (2004). Genetic alterations in locally advanced stage II/III colon cancer: A search for prognostic markers. Clin. Colorectal Cancer. 4:252-259.
Wu, C. C., Chen, H. C., Chen, S. J., Liu, H. P., Hsieh, Y. Y., Yu, C. J., Tang, R., Hsieh, L. L., Yu, J. S., and Chang, Y. S. (2008). Identification of collapsing response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics. 8:316-332.
Zimmermann, U., Balabanov, S., Giebel, J., Teller, S., Junker, H., Schmoll, D., Protzel, C., Scharf, C., Kleist, B., and Walther, R. (2004). Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 209:111-118.
Zimmermann, U., Woenckhaus, C., Teller, S., Venz, S., Langheinrich, M., Protzel, C., Maile, S., Junker, H., and Giebel, J. (2007). Expression of annexin AI in conventional renal cell carcinoma (CRCC) correlates with tumour stage, Fuhrman grade, amount of eosinophilic cells and clinical outcome. Histol. Histopathol. 22:527-534.
Zhang, J. Y., Megliorino, R., Peng, X. X., Tan, E. M., Chen, Y., and Chan, E. K. (2007). Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J. Hepatol. 46:107-114.